𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy

✍ Scribed by Makoto Oketani; Akio Ido; Hirofumi Uto; Hirohito Tsubouchi

Book ID
114944018
Publisher
John Wiley and Sons
Year
2012
Tongue
English
Weight
230 KB
Volume
42
Category
Article
ISSN
1386-6346

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Strategies to prevent hepatitis B virus
Strategies to prevent hepatitis B virus reactivation in patients receiving immunosuppressive therapy
✍ Chiun Hsu; Shu-Chen Wei; Ann-Lii Cheng; Pei-Jer Chen πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 52 KB

prednisone at 50 mg/day and azathioprine at 50 mg/day was initiated. Of note, liver function tests (LFTs) were normal at this time. Two weeks later, the patient was well, prednisone was completely tapered, and azathioprine was increased to 100 mg/day. Three months later, the patient presented to the

Hepatitis B virus (HBV) reactivation aft
Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy β€” pathogenesis and management
✍ Luo Xunrong; Au Wing Yan; Raymond Liang; George K. K. Lau πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 115 KB

## Abstract In an endemic area for chronic hepatitis B infection, reactivation of this virus is a serious cause of morbidity and mortality in patients undergoing cytotoxic or immunosuppressive therapy. Careful prospective serological testing has shown that hepatitis B virus reactivation is a two‐st